A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

US Increases Its Order of the Merck COVID-19 Antiviral Pill


The United States government committed to purchasing 1.7 million doses of molnupiravir—the Merck antiviral medication for COVID-19—in June, and has since increased its order by 1.4 million doses. Molnupiravir has been shown to decrease hospitalizations and deaths by 50% among individuals with COVID-19. The pill, which is taken twice daily for 5 days, would be the first exclusively designed to fight COVID-19. The United Kingdom approved its use for individuals with mild to moderate illness who also have at least one comorbidity. Merck has submitted an application for Emergency Use Authorization to the US Food and Drug Administration, which is scheduled to review it on November 30. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy